Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vasopressor-guided individualized vs fixed-duration hydrocortisone in septic shock (ChiCTR2500111048)
ChiCTR2500111048Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of hydrocortisone in septic shock (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Vasopressor-free days within 28 days after randomization. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
hydrocortisone
03
Conditions
septic shock
Beyond the preview
Go deeper on ChiCTR2500111048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111048.